In an new essay on Health Affairs, Professor Jacob Sherkow writes that the U.S. Supreme Court made the correct decision in Hikma Pharmaceuticals v. Amarin Pharma, giving generic drug manufacturers important protection against patent suits based on labeling approved by the Food and Drug Administration (FDA). This decision will “help preserve patient access to lower-cost medicines,” he writes; however, it also shifts pressure onto FDA, which does not interpret patent claims or decide whether future prescribing will infringe.